Download Image
    
Share
  
Post
Domperidone for COVID-19
1 study with 173 patients
No significant improvements are seen in meta analysis to date.
COVID-19 Domperidone studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -36% Viral clearance -15% RCTs -36% Early -36% Favorsdomperidone Favorscontrol
Recent:
Rabanal Basalo.
Oct 17
2023
 Rabanal Basalo et al., Annals of Medicine, doi:10.1080/07853890.2023.2268535 A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care
36% worse recovery (p=0.23) and 15% worse viral clearance (p=0.62). RCT 173 outpatients with mild-to-moderate COVID-19 showing no significant difference with domperidone versus placebo for viral clearance or symptom recovery.